Table 2.
The 3-, 5-, and 10-year overall survival and prostate cancer-specific mortality of patients after RP, EBRT, and EBRT+BT.
| Therapy | n (%) | Unweighted (%) | Weighted (%) | ||||
|---|---|---|---|---|---|---|---|
| 3-year (95% CI) | 5-year (95% CI) | 10-year (95% CI) | 3-year (95% CI) | 5-year (95% CI) | 10-year (95% CI) | ||
| OVERALL SURVIVAL USING KAPLAN MEIER ANALYSIS | |||||||
| RP | 4,175 (45.8) | 98.3 (97.9–98.7) | 96.2 (95.3–96.9) | 73.5 (54.8–85.5) | 98.4 (98.1–98.7) | 96.8 (96.2–97.2) | 67.5 (49.3–80.4) |
| EBRT | 4,114 (45.1) | 94.0 (93.2–94.6) | 86.3 (86.2–87.6) | 54.7 (39.0–68.0) | 95.1 (94.6–95.6) | 87.3 (86.3–88.2) | 58.0 (49.4–65.6) |
| EBRT+BT | 825 (9.1) | 96.8 (95.3–97.9) | 92.5 (0.89.8–94.5) | 66.5 (35.5–85.2) | 96.7 (96.3–97.1) | 92.8 (92.1–93.5) | 61.5 (47.3–72.9) |
| PROSTATE CANCER-SPECIFIC MORTALITY | |||||||
| RP | 4,175 (45.8) | 6 (4–9) | 16 (12–22) | 17.1 (8–34.3) | 5 (4–7) | 1.4 (1.1–1.7) | 16.3 (8.4–30.1) |
| EBRT | 4,114 (45.1) | 1.9 (1.5–2.4) | 5.3 (4.4–6.4) | 20.8 (13–32.4) | 1.4 (1.2–1.7) | 4.8 (4.2–5.5) | 23.7 (18.6–29.9) |
| EBRT+BT | 825 (9.1) | 1 (0.5–2) | 2.6 (1.5–4.4) | 8.4 (3.6–18.8) | 0.8 (0.6–1) | 2.3 (1.9–2.8) | 6.5 (4.8–8.7) |